The latest advances in the treatment of solid tumors with mRNA tumor vaccine and CLDN6 CAR-T have a disease control rate of 67%

It is reported that BNT211 is a new type of solid tumor CAR-T therapy, which combines autologous CAR-T cell therapy targeting carcinotoembryonic antigen Claudin-6 with the CAR-T cell amplification mRNA vaccine (CARVac) encoding CLDN6, and nearly improves the persistence and anti-tumor activity of CAR-T cells to achieve the effect

The latest data presented on ESMO shows that among the 21 patients with refractory advanced solid tumors who can assess efficacy, the objective response rate (ORR) is 33%, of which 1 person is in complete remission, 6 people are partially in remission, and the disease control rate (DCR) is 67%, of which 14 people have disease progression controlled, which is close to the early data first released at the AACR conference in April this year, but the overall effect has declined

BioNTech highlighted the efficacy of the testicular cancer patient group, with 1 patient in complete remission, 3 patients partially remission, and 2 patients with stable disease (ORR: 57%, DCR: 85%) in 7 patients with testicular cancer, which is close to

It is worth mentioning that 5 of the 10 patients in the combination therapy group of CAR-T cell therapy and mRNA vaccine showed a partial response, while only 2 of the 9 patients in the CAR-T cell therapy group showed a partial response, and did not include two patients who

Overall, CLDN6CAR-T cell therapy alone or in combination with mRNA vaccines, at two different test doses, showed relatively good clinical activity and was well

BioNTech's next stop: the field of oncology

On August 8, BioNTech reported that its revenue for the second quarter of 2022 was 3.

In fact, at the beginning of the development of the new crown vaccine, BioNTech did not regard it as a long-term income, after all, as the vaccination rate continues to rise, the new crown vaccine market will inevitably shrink, and there is also this great uncertainty in
future sales.

At present, BioNTech is driving performance and enriching pipelines through overseas factory construction, mergers and acquisitions, etc.
, and the focus of the layout has gradually shifted to the field of
oncology.

In May 2020, BioNTech acquired Neon for $67 million, acquiring T cell therapy and neoantigen technology
.

In July 2021, BioNTech continued to acquire Kite's TCR R&D platform, which has the role of screening for specific antigen-specific monoclonal TCRs that complement Neon's technology
.

After acquisition and independent research and development, BioNTech's solid tumor cell therapy technology platform has been relatively perfect, and solid tumor treatment products are being developed, of which BNT211 is one of
BioNTech's representative products.

In the era of medical navigation, there is no fixed answer to where the new crown enterprises will go in the future, especially the large enterprises with a wide pipeline layout, after all, there are too many unknown possibilities in the medical field, but conquering tumors is the persistent goal of BioNTech's founder, Ur Shaheen, who said, "After the end of the new crown, we will return to the track
of research and development of cancer treatment.
"
”

By analyzing the pipeline of BioNTech, it can be found that the BioNTech tumor pipeline includes mRNA tumor vaccine, CAR-T cell therapy, TCR-T cell therapy, monoclonal and double antibodies, mRNA antibody drugs, cytokine engineering therapy, etc.
, most of which are indications for products that are solid tumors
.

BioNTech currently has a number of cell therapy products in the clinical stage, of which two self-developed solid tumor CAR-T products (BNT211 and BNT212) are relatively fast
.

In addition, as a leading enterprise in the mRNA industry, BioNTech will also focus on unmet clinical needs and continuously expand the pipeline
of vaccine products beyond the new crown.

Overall, at the moment when the new crown vaccine market is shrinking, BioNTech is giving full play to the advantages of its mRNA industry giants, with mRNA technology as the basis for radiation to different fields such as cell therapy and antibodies, the focus of the track has gradually shifted from new crown to tumors, and is taking advantage of the new crown vaccine to go overseas to penetrate the global market
.

epilogue

Actively laying out the field of oncology is the focus of BioNTech's next strategy, and its new CAR-T therapy BNT211 for the treatment of patients with recurrent or refractory advanced solid tumors has shown initial therapeutic results
.

The epidemic will eventually pass, the future of the new crown related revenue will be predictably contracted, BioNTech expects to use its own mRNA technology advantages and extensive layout of the oncology field to cope with the business downward cycle, other vaccine giants are also actively seeking new performance growth points, who can cross the pharmaceutical downward cycle, let time witness
.

Resources:

1.
https://investors.
biontech.
de/news-releases/news-release-details/biontech-presents-encouraging-phase-12-follow-data-car-t

——List of recent hot events——

▼On September 21, Merck China Biosafety Testing Center was opened